<DOC>
	<DOCNO>NCT01999985</DOCNO>
	<brief_summary>The purpose study : - Find study drug Afatinib Dasatinib safely give together patient lung cancer - Learn two drug work cancer cell combine - Learn side effect two drug combine - Find high dos study drug Afatinib Dasatinib give safely without cause serious side effect</brief_summary>
	<brief_title>Phase I Trial Afatinib ( BIBW 2992 ) Dasatinib Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Pathologically cytologically document Stage IIIB/IV nonsmall cell lung cancer , unresectable recurrent disease follow locoregional treatment . For Phase 1B Extension Only : Either follow : A tumor harbor activate Epidermal Growth Factor Receptor ( EGFR ) mutation ; History objective response , stable disease least 6 month , treatment erlotinib , afatinib , gefitinib . Either follow : Progression recurrence disease receive prior continuous gefitinib , afatinib , erlotinib ; A tumor know harbor de novo T790M mutation , know confer EGFR TKI resistance . Participants allow received systemic chemotherapy investigational therapy intervening period prior trial enrollment Capable give write informed consent . Evaluable disease , follow : For Phase 1A Dose Escalation : Have presence evaluable disease , include bone metastasis , effusion , cystic metastasis . For Phase 1B Extension Only : Have progressive measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST v 1.1 ) . Reproductive potential must either terminate ( surgery , radiation , menopause ) attenuate use approve contraceptive method 3 6 month follow study . Participant agree IV bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia . Have recover prior drugrelated toxicity Grade ≤ 1 Common Terminology Criteria Adverse Events ( CTCAE ) v4 , within 21 day initiation onstudy treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 initial enrollment , assess clinician investigator . Have previously complete withdrawn study study investigate dasatinib . Prior treatment tyrosine kinase , include afatinib , acceptable . Prior recent systemic investigational therapy within 21 day initiation study treatment . An exception epidermal growth factor receptor ( EGFR ) inhibitor may continue 3 day initiation study treatment . Women pregnant breastfeeding . Women childbearing potential must negative pregnancy test ( βHCG test urine serum ) prior commence study treatment . Patients documented central nervous system leptomeningeal metastasis ( brain metastasis ) time study entry . Patients prior brain metastasis may consider complete treatment brain metastasis longer require corticosteroid . Patients disease progression central nervous system ( CNS ) . Serious concomitant disorder , include active bacterial , fungal , viral infection , incompatible study ( discretion principal investigator ) . Uncorrected severe electrolyte disorder , include severe potassium ( &lt; 3.0 mEq/L ) magnesium ( &lt; 1.0 mEq/L ) deficiency . Any gastrointestinal disorder diarrhea major symptom , Crohn 's , preexist chronic diarrhea Common Toxicity Criteria ( CTC ) Grade ≥ 2 etiology . Included malabsorption disorder opinion study physician may affect absorption either afatinib dasatinib . Prior major surgery radiation therapy within 14 day initiation treatment . Electrocardiogram ( ECG ) abnormalities indicative arrhythmia ( discretion investigator ) . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association ( NYHA ) classification 3 , unstable angina poorly control arrhythmia . Myocardial infarction within 6 month prior enrollment . Baseline ( &lt; 1 month treatment ) cardiac leave ventricular function rest ejection fraction le 50 % measure multigated blood pool image heart ( MUGA scan ) echocardiogram . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , congenital long QT syndrome , Torsades de pointes ) . Prolonged QTc interval preentry electrocardiogram ( &gt; 470 msec men &gt; 480 msec woman per American College Cardiology/American Heart Association [ AHA/ACC ] 2011 scientific statement ) . History significant bleeding disorder unrelated cancer , include diagnose congenital bleeding disorder ( e.g. , von Willebrand 's disease ) . Patients currently take drug generally accept high risk cause Torsades de Pointes . Patients preexist interstitial lung disease ( ILD ) , pericardial / pleural effusion grade 2 high . Trace pericardial pleural effusion acceptable . Patients require chronic oxygen therapy chronic obstructive pulmonary disease pleural effusion ( malignant benign ) . Patients require comedication potent Pgp inhibitor ( include cyclosporin , azithromycin , erythromycin , ketoconazole , itraconazole , quinidine , phenobarbital salt quinidine , ritonavir , valspodar , verapamil ) inducer ( include rifampicin ) . Known active hepatitis B infection , know active hepatitis C infection , know HIV carrier . Known suspected active drug alcohol abuse . Known hypersensitivity afatinib , dasatinib , excipients trial drug . Laboratory exclusion criterion : Absolute neutrophil count ( ANC ) &lt; 1000 / mm^3 , Platelet count &lt; 100,000 / mm^3 , Serum creatinine ≥1.5 time upper normal limit calculated/measured creatinine Clearance ≤60 mL/min. , Total bilirubin ≥1.5 mg/dL ( &gt; 26 mol/L , SI unit equivalent ) , Aspartate amino transferase ( AST ) Alanine amino transferase ( ALT ) ≥ 2.5 time upper limit normal ( related liver metastasis ≥ five time upper limit normal ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Epidermal Growth Factor Receptor ( EGFR )</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Pleural Diseases</keyword>
	<keyword>Pleural Neoplasms</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Pleural Effusion</keyword>
	<keyword>Pleural Effusion , Malignant</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Thoracic Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>Afatinib</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Carcinoma , Bronchogenic</keyword>
	<keyword>Gene Mutation</keyword>
	<keyword>T790M mutation .</keyword>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>